Vasospasm after aneurysmal subarachnoid hemorrhage: Need for further study

Acta Neurochirurgica, Supplementum

Volumn , Issue 105, 2008, Pages 207-210

  Pearl, J D ^a   MacDonald, R L ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Cerebral aneurysm; clazosentan; endothelin antagonist; subarachnoid hemorrhage; vasospasm

Indexed keywords

CLAZOSENTAN; ENDOTHELIN 1; DIOXANE DERIVATIVE; ENDOTHELIN; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; SULFONAMIDE; TETRAZOLE DERIVATIVE;

BRAIN ARTERY ANEURYSM RUPTURE; BRAIN BLOOD FLOW; BRAIN INFARCTION; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; BRAIN VASOSPASM; CLINICAL EVALUATION; CONVENTIONAL ANGIOGRAPHY; GLASGOW OUTCOME SCALE; HUMAN; MEDICAL RESEARCH; MICROANGIOPATHY; MORTALITY; PATHOGENESIS; PROGNOSIS; RANKIN SCALE; RISK BENEFIT ANALYSIS; SHORT SURVEY; SPREADING CORTICAL DEPRESSION; SUBARACHNOID HEMORRHAGE; THROMBOEMBOLISM; DRUG ANTAGONISM; PATHOLOGY; PHASE 2 CLINICAL TRIAL; REVIEW;

CLINICAL TRIALS, PHASE II AS TOPIC; DIOXANES; ENDOTHELINS; HUMANS; PYRIDINES; PYRIMIDINES; SUBARACHNOID HEMORRHAGE; SULFONAMIDES; TETRAZOLES; VASOSPASM, INTRACRANIAL;

EID: 64249172026     PISSN: 00651419     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-211-09469-3_39     Document Type: Short Survey

References (12)

1. Barth M, Capelle HH, Munch E, Thome C, Fiedler F, Schmiedek P, Vajkoczy P (2007) Effects of the selective endothelin A (ET (A)) receptor antagonist Clazosentan on cerebral perfusion and cerebral oxygenation following severe subarachnoid hemorrhage - preliminary results from a randomized clinical series. Acta Neurochir (Wien) 149:911-918
2. Fergusen S, Macdonald RL (2007) Predictors of cerebral infarction in patients with aneurysmal subarachnoid hemorrhage. Neurosurgery 60:658-667
3. Fernandez A, Schmidt JM, Claassen J, Pavlicova M, Huddleston D, Kreiter KT, Ostapkovich ND, Kowalski RG, Parra A, Connolly ES, Mayer SA (2007) Fever after subarachnoid hemorrhage: risk factors and impact on outcome. Neurology 68:1013-1019
4. Findlay JM, Kassell NF, Weir BK, Haley EC Jr, Kongable G, Germanson T, Truskowski L, Alves WM, Holness RO, Knuckey NW (1995) A randomized trial of intraoperative, intracisternal tissue plasminogen activator for the prevention of vasospasm. Neurosurgery 37:168-178
5. Leung CH, Poon WS, Yu LM, Wong GK, Ng HK (2002) Apolipoprotein E genotype and outcome in aneurysmal subarachnoid hemorrhage. Stroke 33:548-552
6. Macdonald RL, Kreiter KT, Mayer SA, Knappertz V (2005) Methodology for phase 3 clinical trial planning: powering treatment studies of vasospasm in SAH. J Neurosurg 102: A416
7. Macdonald RL, Pluta RM, Zhang JH (2007) Cerebral vasospasm after subarachnoid hemorrhage: the emerging revolution. Nat Clin Pract Neurol 3:256-263
8. Nolan CP, Macdonald RL (2006) Can angiographic vasospasm be used as a surrogate marker in evaluating therapeutic interventions for cerebral vasospasm? Neurosurg Focus 21: E1
9. Rosengart AJ, Schultheiss KE, Tolentino J, Macdonald RL (2007) Prognostic factors for outcome in patients with aneurysmal subarachnoid hemorrhage. Stroke 38:2315-2321 (Pubitemid 47457575)
10. Roux S, Breu V, Giller T, Neidhart W, Ramuz H, Coassolo P, Clozel JP, Clozel M (1997) Ro 61-1790, a new hydrosoluble endothelin antagonist: general pharmacology and effects on experimental cerebral vasospasm. J Pharmacol Exp Ther 283:1110-1118
11. Stevens RD, Nyquist PA (2007) The systemic implications of aneurysmal subarachnoid hemorrhage. J Neurol Sci 261:143-156
12. Vajkoczy P, Meyer B, Weidauer S, Raabe A, Thome C, Ringel F, Breu V, Schmiedek P (2005) Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: results of a randomized, double-blind, placebo-controlled, multicenter phase IIa study. J Neurosurg 103:9-17